Refractory Focal Onset Epilepsy- Biohaven BHV7000-303
Participating in a clinical trial with Profound means making a real difference in the lives of others facing similar health challenges.
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
Key Inclusion Criteria:
- Male and Female participants 18 to 75 years of age at time of consent.
- Diagnosis of Focal Onset Epilepsy at least 1 year prior to screening visit defined by 2017 International League Against Epilepsy (ILAE) Classification and based on requirements of Epilepsy Adjudication criteria.
- Focal seizures i. Focal aware seizures with clinically observable signs and/or symptoms ii. Focal impaired awareness seizures with clinically observable signs and/or symptoms iii. Focal to bilateral tonic-clonic seizures
- Subject meets the 2009 ILAE definition of drug-resistant epilepsy, failure of adequate trials of two tolerated and appropriately chosen and used anti-seizure medication (ASM) schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom.
- Ability to keep accurate seizure diaries
- Current treatment with at least 1 and up to 3 ASMs and 4 epilepsy treatments in total
- Other criteria may apply
Complete the form and our team will reach out soon to help determine your eligibility.
